BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8856090)

  • 1. Biological and clinical significance of in vitro prednisolone resistance in adult acute lymphoblastic leukaemia.
    Tosi P; Visani G; Ottaviani E; Manfroi S; Tura S
    Eur J Haematol; 1996 Aug; 57(2):134-41. PubMed ID: 8856090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
    Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
    Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro culture with prednisolone increases BCL-2 protein expression in adult acute lymphoblastic leukemia cells.
    Tosi P; Visani G; Ottaviani E; Manfroi S; Tura S
    Am J Hematol; 1996 Apr; 51(4):261-4. PubMed ID: 8602624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.
    Kaspers GJ; Veerman AJ; Pieters R; Van Zantwijk CH; Smets LA; Van Wering ER; Van Der Does-Van Den Berg A
    Blood; 1997 Oct; 90(7):2723-9. PubMed ID: 9326239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive chemotherapy for acute lymphoblastic leukaemia in adults.
    Rohatiner AZ; Bassan R; Battista R; Barnett MJ; Gregory W; Lim J; Amess J; Oza A; Barbui T; Horton M
    Haematol Blood Transfus; 1990; 33():413-8. PubMed ID: 2182432
    [No Abstract]   [Full Text] [Related]  

  • 6. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
    Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
    J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group.
    Kobayashi T; Tobinai K; Shimoyama M; Mikuni C; Konda S; Kozuru M; Araki K; Sai T; Fukuhara S; Matsumoto M; Aoki I; Deura K; Oyama A; Hotta T; Abe T; Toki H; Nagai M; Fukuda H; Niimi M; Yamaguchi N; Tajima K; Shirakawa S
    Jpn J Clin Oncol; 1999 Jul; 29(7):340-8. PubMed ID: 10470659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
    Yetgin S; Cetin M
    Leuk Lymphoma; 2003 Mar; 44(3):489-95. PubMed ID: 12688320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival in acute lymphoblastic leukaemia in adults: a prospective study of 51 patients. Finnish Leukaemia Group.
    Eur J Haematol; 1992 Feb; 48(2):75-82. PubMed ID: 1547879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
    Ravandi F; Cortes J; Estrov Z; Thomas D; Giles FJ; Huh YO; Pierce S; O'Brien S; Faderl S; Kantarjian HM
    Leuk Res; 2002 Jul; 26(7):643-9. PubMed ID: 12008081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive treatment improves survival in adult acute lymphoblastic leukemia.
    Smedmyr B; Killander A; Simonsson B; Sundström C
    Eur J Haematol; 1988 Nov; 41(5):478-81. PubMed ID: 3208869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia.
    Nagura E; Kimura K; Yamada K; Ota K; Maekawa T; Takaku F; Uchino H; Masaoka T; Amaki I; Kawashima K
    Cancer Chemother Pharmacol; 1994; 33(5):359-65. PubMed ID: 8306408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
    Hongo T; Yamada S; Yajima S; Watanabe C; Fujii Y; Kawasaki H; Yazaki M; Hanada R; Horikoshi Y
    Int J Hematol; 1999 Dec; 70(4):268-77. PubMed ID: 10643153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia.
    Xu B; Song X; Yip NC; Xiao P; Zhang Y; Wang W; Zhou S
    Hematology; 2010 Apr; 15(2):74-80. PubMed ID: 20423567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The programmed therapy of acute lymphoblastic leukemia in adults].
    Isaev VG; Savchenko VG; Kucher RA; Abakumov EM; Parovichnikova EN
    Ter Arkh; 1992; 64(8):82-7. PubMed ID: 1440405
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia.
    Coustan-Smith E; Kitanaka A; Pui CH; McNinch L; Evans WE; Raimondi SC; Behm FG; Aricò M; Campana D
    Blood; 1996 Feb; 87(3):1140-6. PubMed ID: 8562940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
    Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S;
    Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.
    Pieters R; Huismans DR; Loonen AH; Hählen K; van der Does-van den Berg A; van Wering ER; Veerman AJ
    Lancet; 1991 Aug; 338(8764):399-403. PubMed ID: 1678081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of adult acute lymphoblastic leukemia with Ad-VP-L regimen].
    Umeda M; Shikoshi K; Anno S; Su CY; Shirai T
    Rinsho Ketsueki; 1991 Jan; 32(1):6-10. PubMed ID: 2020119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
    Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
    Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.